Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 8,146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Metastatic Melanoma, Unresectable Melanoma
Interventions: IO102-IO103, Pembrolizumab; Drug
Lead sponsor: IO Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Orange City, Florida • Orlando, Florida • Buffalo, New York + 1 more

Conditions: Infant Death, Sudden Infant Death
Interventions: TodaysBaby; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Non-hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Mesothelioma, Peritoneal Mesothelioma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more

Conditions: Glioblastoma
Interventions: Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 11
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more

Conditions: SCHIZOPHRENIA 1 (Disorder)
Interventions: Paliperidone Palmitate; Drug
Lead sponsor: Alejandro Alva; Network
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Orange, California • Miami, Florida • Chicago, Illinois

Conditions: Spinal Cord Injury
Interventions: Somatosensory Stimulation and Massed Practice Training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 3
States / cities: Gainesville, Florida • Charleston, South Carolina • Nashville, Tennessee

Conditions: Dermatitis, Atopic
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more

Conditions: Hypertension
Interventions: Levamlodipine, Amlodipine, Amlodipine, Levamlodipine; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Unilateral Hearing Loss
Interventions: Hearing aid; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 6 Years to 12 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Glucose, Blood Insulin
Interventions: Fruit snack 1, Fruit snack 2, Fruit snack 3, Fruit snack 4, Fruit snack 5, Confection control; Dietary Supplement
Lead sponsor: Ocean Spray Cranberries, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Sleep Control Condition, Insomnia Symptoms Induction Condition
Interventions: Insomnia symptom induction; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Bleeding, Arterial Puncture, Catheter Complications, Occlusion of Artery
Interventions: Heparin, Terumo Radial Band, Vaosband; Drug · Device
Lead sponsor: Regional Hospital of Scranton; Other
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Myopia
Interventions: Atropine; Drug
Lead sponsor: State University of New York College of Optometry; Other
Eligibility: 18 Years to 35 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: TAK-418, TAK-418 Matching Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Salt Lake City, Utah

Conditions: Cancer Survivorship
Interventions: Conexiones, Taking Time; Behavioral
Lead sponsor: New Mexico State University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Las Cruces, New Mexico • El Paso, Texas • San Antonio, Texas

Conditions: 21-hydroxylase Deficiency
Interventions: Abiraterone acetate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas

Conditions: Gestational Diabetes
Interventions: Continuous glucose monitoring (CGM), Self-Capillary Blood Glucose Monitoring (SCBG); Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions: Lidoderm; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more

Conditions: Shwachman-Diamond Syndrome
Interventions: Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires; Diagnostic Test · Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Get Social Media and Risk-Reduction Training

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Higher-Dose Maintenance With ERZOFRI 351 mg in Adults With Schizophrenia

Effect of Prolonged Electrical Stimulation on Neural Plasticity in Spinal Cord Injury

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

A Study of LY3471851 in Participants With Eczema

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Use of Amplification in Children With Unilateral Hearing Loss

Monitoring Postprandial Blood Glucose and Insulin in Fruit Snacks

Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms

Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

The Effects of Low Dose Atropine on Choroidal Thickness

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Taking Time to Connect: A Study of Programs for Hispanic Mothers Diagnosed With Cancer and Their Children

A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency

Time-in-range Using Continuous Glucose Monitoring Management of Gestational Diabetes Mellitus

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

Diabetes/ Endocrine Surveillance in SDS